SCHEMBL1498592

SCHEMBL1498592

CCCC[Sn](CCCC)(CCCC)c1cccc(C(OC)OC)n1

nearest known ligand 0.32

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.32
KMT2A Q03164 1/20 0.32
KCNH2 Q12809 1/20 0.31
L3MBTL1 Q9Y468 2/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL906580 0.83 KCNH2 (0.33) KCNH2
SCHEMBL29579616 0.83 KCNH2 (0.33) KCNH2
SCHEMBL2482179 0.81 KCNH2 (0.33) KCNH2
SCHEMBL6639407 0.78 GCGR (0.30) KCNH2
SCHEMBL153619 0.76 PDE10A (0.35) KCNH2
SCHEMBL29779695 0.76 PDE10A (0.35) KCNH2
SCHEMBL3748371 0.75 KCNH2 (0.37) KCNH2
SCHEMBL29865866 0.74 CCR1 (0.39) RAB9AKMT2AKCNH2L3MBTL1POLB
SCHEMBL246415 0.74 CCR1 (0.39) RAB9AKMT2AKCNH2L3MBTL1POLB
SCHEMBL23782512 0.74 CYP1A2 (0.44) RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9187690-B2 Rare earth metal complex having phenanthroline compound as ligand B.R.A.H.M.S. GMBH (DE) 2015-11-17 US disclosed
EP-2683725-B1 RARE EARTH METAL COMPLEX HAVING PHENANTHROLINE COMPOUND AS LIGAND BRAHMS GMBH (DE) 2015-08-26 EP disclosed
EP-2477986-B1 PHENANTHROLINE DERIVATIVES AND THEIR USE AS LIGANDS BRAHMS GMBH (DE) 2014-11-12 EP disclosed
US-20140058073-A1 RARE EARTH METAL COMPLEX HAVING PHENANTHROLINE COMPOUND AS LIGAND B.R.A.H.M.S. GMBH (DE) 2014-02-27 US disclosed
US-8648194-B2 Compounds having phenanthroline structure B.R.A.H.M.S GMBH (DE) 2014-02-11 US disclosed
EP-2683725-A1 RARE EARTH METAL COMPLEX HAVING PHENANTHROLINE COMPOUND AS LIGAND B.R.A.H.M.S GmbH (DE) 2014-01-15 EP disclosed
US-20120238748-A1 NOVEL COMPOUNDS HAVING PHENANTHROLINE STRUCTURE B.R.A.H.M.S GMBH (DE) 2012-09-20 US disclosed
WO-2012124310-A1 RARE EARTH METAL COMPLEX HAVING PHENANTHROLINE COMPOUND AS LIGAND B.R.A.H.M.S GMBH (DE) 2012-09-20 WO disclosed
EP-2477986-A1 PHENANTHROLINE DERIVATIVES AND THEIR USE AS LIGANDS B.R.A.H.M.S GmbH (DE) 2012-07-25 EP disclosed
WO-2011030566-A1 PHENANTHROLINE DERIVATIVES AND THEIR USE AS LIGANDS EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238748-A1 NOVEL COMPOUNDS HAVING PHENANTHROLINE STRUCTURE PAH, BPTF, HDAC1 RAB9A 1777/4885KMT2A 506/4885KCNH2 890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.